Drug Combination Details
| General Information of the Combination (ID: C49186) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | Sunitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| In-vivo Model | Caki-1 cells (2x106) in 100 ul RPMI-1640 and 100 ul of matrigel were used to inject subcutaneously into each mouse (5-week-old male athymic BALB/c nu/nu mice). | |||||
| Experimental
Result(s) |
The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(12):6463-8. | |||
